Preventing Stockouts of Essential TB Drugs: QuanTB 2.0

Preventing Stockouts of Essential TB Drugs: QuanTB 2.0

 {Photo credit: Mark Tuschman.}A pharmacy in Kenya.Photo credit: Mark Tuschman.

Guaranteeing that patients have uninterrupted access to anti-tuberculosis (TB) treatment begins with national TB programs (NTP) making complex calculations about how many cases to expect in the future.  Vigilant stock management, accurate number of cases started on each type of treatment along with forecasting the expected number of patients that will be enrolled on treatment, are vital to ensure that medicines are available to all patients who need them.

To promote a systems-strengthening approach to TB medicines management, the US Agency for International Development (USAID)-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) program developed QuanTB—a downloadable, desktop tool that transforms intricate calculations into a user-friendly dashboard displaying key quantification and supply planning information.

QuanTB improves procurement processes, ordering and planning for TB treatment. By alerting users to risks of stock-out and overstock, QuanTB operates as an early warning mechanism. SIAPS has trained NTP drug management staff and partners from twelve countries to use QuanTB; of these, nine* have adopted it as the national tool for quantification and monitoring of TB medicines (Bangladesh*, Ethiopia*, Kenya*, Malawi, Mozambique, Nigeria, Philippines*, Tajikistan*, Tanzania*, Uganda*, Zambia*, Zimbabwe*.) SIAPS also worked with the Stop TB Partnership Global Drug Facility (GDF) to integrate QuanTB with the early warning stock-out system as a part of global forecasting for TB medicines.

Within the first six months of implementing the tool, six countries reported to SIAPS on their use of QuanTB for medicines tracking and the decisions made based on QuanTB data. Results were impressive: the percentage of countries that reported a stock-out of at least one first-line TB medicine decreased from 100 percent (5/5) to 0 percent (0/5), while the percentage of countries that reported a stock-out of at least one second-line TB medicine dropped from 50 percent (3/6) to 17 percent (1/6).

In Bangladesh, SIAPS partnered with the NTP, WHO, and local TB organizations, using QuanTB to analyze the rates at which TB patients were enrolling in treatment and refine projections about how many cases to expect in the future. As a result of these calculations, the NTP identified certain medicines that were overstocked and likely to expire before being used, and others that were at risk of stocking out based upon QuanTB outputs. SIAPS then led the partnership in using QuanTB to determine the most effective ways to adjust orders. As a result, Bangladesh was able to postpone and reallocate about 2.5 million dosages of TB medicines shipments, saving over $899,000 USD of country and donor funding.

The new QuanTB (version 2.0.0) is available for download, along with a comprehensive user guide, on the SIAPS website at: siapsprogram.org/quantb.

Feedback and questions are welcome through the QuanTB forum.

 

Correction, April 3, 2015: This post was updated to correct an inadvertent data error: stock-out of at least one second-line TB medicine started at 50 percent (3/6) -- not 67 percent (4/6) as was originally reported --and dropped to 17 percent (1/6).

Correction, Nov. 21, 2014: This post originally listed the Global Drug Facility as affiliated with the World Health Organization (WHO). The post was updated to reflect the correct name: Stop TB Partnership Global Drug Facility. (Formerly part of the World Health Organization (WHO), the Stop TB Secretariat moved to the United Nations Office for Project Services (UNOPS) in July, 2014.)

Add new comment

Printer Friendly VersionPDF